Polycystic Ovary Syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. It has been reported that PCOS is an endocrinopathy resulting from insulin resistance and compensatory hyper-insulinemia. This syndrome effect multiple organ systems and may result in serum lipid changes, anovulation, abnormal uterine bleeding, hirsutismus, and infertility. In addition, this syndrome constitue a risk for the development of type 2 diabetes, hypertension, endometrial cancer, and cardiovascular disease. Standart therapy modalities are oral contraceptives, progestins, anti-androgens, and ovulation induction agents. However, insulin-sensitizing agents are now being shown to be useful alone or combined with standart therapies.